

Monkeypox vaccine maker Bavarian Nordic ready to meet demand

June 23 2022, by Camille BAS-WOHLERT



A picture made available by the UK Health Security Agency showing a range of monkeypox lesions.

As the lone laboratory manufacturing a licensed vaccine against monkeypox, Danish company Bavarian Nordic has seen its order book

fill up as the usually rare disease spreads around the world.

"The approval we got in 2019, when we only sold maybe a few hundred doses, all of a sudden became very, very relevant for [international health](#)," the company's vice president Rolf Sass Sorensen says with a smile at the biotech company's headquarters in Copenhagen's harbour.

Bavarian Nordic was caught by surprise by the disease's sudden spread earlier this year to dozens of countries outside West and Central Africa where it had previously been generally confined.

But Sorensen says he is confident the company can meet global demand even though it only has one [production facility](#).

"With the current demand we can easily supply the global market. We have a couple of million doses in bulk that we can put into vials and make sure that the current outbreak is handled," he told AFP in an interview.

Bavarian Nordic has an annual production capacity of 30 million [vaccine doses](#).

The Danish company's smallpox [vaccine](#), marketed as Imvanex in Europe, Jynneos in the US and Imvamune in Canada, is a third-generation serum (a live vaccine that does not replicate in the human body).

It has been licensed in Europe since 2013.

It was designed against smallpox in adults, a disease considered eradicated some 40 years ago, and requires two doses for inoculation.

World clamouring for vaccine

According to Sorensen, the vaccine is in stock "in many countries" and can also be used against monkeypox, both before and after exposure to the virus.


"If you are vaccinated a few days after you are exposed, you can also be protected", he explained.

After getting the [green light](#) from the US Food and Drug Administration (FDA) three years ago to use its smallpox vaccine against monkeypox, Bavarian Nordic is now applying to do the same in Europe.

The European Health Emergency Preparedness and Response Authority (HERA), created by the European Commission during the Covid-19 pandemic, has already bought more than 100,000 doses for the 27 EU countries as well as Norway and Iceland.

Monkeypox

Zoonotic viral disease that occurs primarily in tropical rainforest areas of Central and West Africa



A member of the *Orthopoxvirus* genus, which includes smallpox

Origins

First identified in humans in 1970 in DR Congo

Most cases reported from rainforest regions of the Congo Basin, particularly in the DR Congo

Considered endemic in several African nations

Mostly transmitted to people from wild animals such as rodents and primates

Person-to-person transmission possible by contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding



Not considered to be highly contagious between people


Source: ECDC/WHO/UN

Current outbreaks

As of June 14

- ▶ 1,600 confirmed cases reported to WHO
- ▶ 1,500 suspected cases
- ▶ In 39 countries, of which 32 are in non-endemic regions

• Non-endemic countries with confirmed cases



Endemic countries

72 deaths in endemic countries so far this year

UNAIDS said "a significant proportion" of recent monkeypox cases has been identified among gay, bisexual and other men who have sex with men

But transmission is most likely via close physical contact and could affect anyone

The disease

- ▶ Incubation usually 6 to 16 days
- ▶ Symptoms usually last 2 to 4 weeks

General symptoms

- Fever • Headache • Backache
- Muscle aches • Chills • Swollen lymph nodes

Rash



Often begins on the face
Spreads to other parts of body, including genitals
Rash forms into lesions which form a scab and eventually fall off

- ▶ Most people recover within weeks
- ▶ Up to a tenth of persons infected may die, with most deaths occurring in younger age groups
- ▶ Smallpox vaccines have been found to be about 85% effective; however access is limited as smallpox has been eradicated



Factfile on monkeypox and its current outbreak.

The first deliveries are due at the end of June for those countries deemed a priority.

The United States has also filled up their stocks with an order for 500,000 doses, in addition to 100 million doses of an older [smallpox vaccine](#) previously made by France's Sanofi but which is known to have

some side effects.

Canada and Denmark have also placed orders with Bavarian Nordic.

Other than these announcements made by the countries themselves, Bavarian Nordic—which also makes vaccines against tick-borne encephalitis, rabies, Ebola, Covid-19 and the RS respiratory virus—does not disclose which countries have placed orders.

"But I can say we have procurement requests from all over the world. We have procurement requests from the US, European countries, Middle Eastern countries, Asian countries", Sorensen said.

The value of the contracts hasn't been disclosed either, but for Bavarian Nordic it has clearly been a windfall: it raised its 2022 full-year outlook four times in three weeks.

Rarely fatal

Despite the rise in monkeypox cases worldwide, the World Health Organization has not recommended that countries mass vaccinate their populations at this stage.

The United States has so far recommended the vaccination of people who have been in close contact with an infected person, while France has recommended a single dose for contact cases in risk groups who were vaccinated for smallpox before 1980.

The European Medicines Agency approved a smallpox medication, Tecovirimat, for treatment of monkeypox earlier this year, but it is not yet widely available.

Most people recover from monkeypox within several weeks and the

disease has only been fatal in rare cases.

Symptoms include lesions, eruptions on the face, palms or soles, scabs, fever, muscle ache and chills.

From January 1 to June 15, the WHO registered more than 2,103 cases and one death in 42 countries.

Europe has been the epicentre of the outbreak, with 1,773 confirmed cases, or 84 percent of the global total.

© 2022 AFP

Citation: Monkeypox vaccine maker Bavarian Nordic ready to meet demand (2022, June 23) retrieved 27 April 2024 from

<https://medicalxpress.com/news/2022-06-monkeypox-vaccine-maker-bavarian-nordic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.